I. The goal of hypertension to lower blood pressure 1. The blood pressure of ordinary hypertensive patients should be controlled below 140/90mmHg; 2. The hypertension of those who also have diabetes, cerebrovascular disease, stable coronary heart disease, chronic kidney disease and the hypertension of young people should be lowered to below 130/80mmHg. 3, hypertension in the elderly (65 years of age or older) should be reduced to below 150/90mmHg. However, the diastolic blood pressure of patients with coronary artery disease and advanced age should be concerned when it is below 60mmHg. 4.If tolerated, the blood pressure of all the above patients can be further reduced, and it is recommended to lower the blood pressure to below 120/80mmHg as much as possible. 5, hypertension treatment blood pressure attainment time: in general, 1-2 level hypertension treatment for blood pressure attainment within 4-12 weeks; if the patient treatment is poorly tolerated or the elderly attainment time can be extended appropriately. Second, the glucose reduction target of diabetes 1, fasting blood sugar to 3.9~7.2mmol/L; 2, non-fasting blood sugar to less than 10mmol/L; 3, glycated hemoglobin to less than 7.0%. Blood glucose control target must be individualized, and the target of blood glucose control for children, the elderly and those with serious comorbidities can be wider than the general population (e.g. fasting blood glucose <8.0mmol/L, 2 hours postprandial blood glucose <10.0mmol/L, glycosylated hemoglobin <7.5%) to avoid the occurrence of hypoglycemia. Patients with a history of severe or frequent hypoglycemia should also not set strict glycemic control goals. Experts warn of the dangers of hypoglycemia: a serious hypoglycemia and the resulting physical damage can offset the benefits of a lifetime of blood glucose control. Third, the goal of hyperlipidemia control Treatment of hyperlipidemia (dyslipidemia) begins with a determination of the patient's risk of future cardiovascular disease events. Risk factors for cardiovascular disease other than hypertension are: ① age (male) ≥ 45, (female) ≥ 55, ② smoking, ③ HDL-C (high-density lipoprotein cholesterol) <1.04 mmol/L, ④ obesity (body mass index ≥ 28 kg/m2), ⑤ family history of early onset ischemic cardiovascular disease, early onset that is first-degree male (female) relatives, onset before 55 (65) years of age, ischemic Cardiovascular disease refers to coronary heart disease, ischemic stroke. Very high risk: ① acute myocardial infarction, ② unstable angina, ③ ischemic cardiovascular disease (coronary heart disease and ischemic stroke) combined with diabetes mellitus - → total cholesterol (TC) ≥ 4.14 mmol/L, low-density lipoprotein cholesterol (LDL-C) ≥ 2.07 mmol/L when starting to take lipid-lowering drugs, so that The former should be reduced to below 3.11mmol/L and the latter to below 2.07mmol/L. High risk: ① coronary heart patients, ② diabetic patients, ③ ischemic stroke, ④ transient ischemic attack, TC>5.18mmol/L and LDL-C>3.37mmol/L from ① to ④, ⑤ hypertension and other risk factors ≥1 as well as TC≥6.22mmol/L and LDL-C≥4.14mmol/L- -→Total cholesterol (TC) ≥ 4.14 mmol/L and LDL-C ≥ ≥ 2.59 mmol/L when starting lipid-lowering drugs to reduce the former to below 4.14 mmol/L and the latter to below 2.59 mmol/L. Intermediate risk: without coronary heart disease and diabetes, ① hypertension and other risk factors ≥1 as well as TC5.18-6.19mmol/L, LDL-C3.37-4.12mmol/L, ② hypertension and no other risk factors as well as TC≥6.22mmol/L, LDL-C≥4.14mmol/L, ③ no hypertension and other risk factors ≥3 as well as TC (3) Those without hypertension and with ≥3 other risk factors and TC ≥6.22mmol/L and LDL-C ≥4.14mmol/L -→ Start taking lipid-lowering drugs when total cholesterol (TC) ≥6.22mmol/L and LDL-C ≥4.14mmol/L to bring the former down to below 5.18mmol/L and The latter was reduced to below 3.37 mmol/L. Low risk: no coronary heart disease and diabetes mellitus, ① hypertension and no other risk factors and TC5.18-6.19mmol/L, LDL-C3.37-4.12mmol/L, ② no hypertension and other risk factors ≥3 and TC5.18-6.19mmol/L, LDL-C3.37-4.12mmol/L, ③ no hypertension and other risk Number of risk factors <3 as well as TC ≥5.18mmol/L, LDL-C ≥3.37mmol/L -→ Start taking lipid-lowering drugs when total cholesterol (TC) is greater than 6.99mmol/L and LDL-C is greater than 4.92mmol/L to bring the former down to 6.22mmol/L or less and the latter to 4.14mmol/L or less. In severe hypertriglyceridemia (≥5.65mmol/L), in order to prevent the occurrence of acute pancreatitis, triglycerides should first be actively lowered in mild to moderate elevated triglycerides (2.26-5.64mmol/L): Step 1: first determine the patient's cardiovascular disease risk stratification (very high risk, high risk, moderate risk, low risk); Step 2: LDL-C attainment is the primary goal (very high risk < 2.07 mmol/L, high-risk <2.59 mmol/L, intermediate-risk <3.37 mmol/L, low-risk <4.14 mmol/L); step 3: non-HDL-C (TC minus HDL-C) attainment as a secondary goal (very high risk <2.85 mmol/L, high-risk <3.37 mmol/L, intermediate-risk <4.15 mmol/L, low-risk < (4.92mmol/L). Step 4: After all of the above are met, consider triglyceride lowering with drugs such as fibrates only if necessary (some experts suggest that fibrates are preferred to achieve the non-HDL-C standard). Critically elevated triglycerides (1.70-2.25 mmol/L): non-pharmacological treatment.